Operator

Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics First Quarter 2026 Conference Call. [Operator Instructions] This call is being recorded on Tuesday, May 12, 2026.

I would now like to turn the conference over to our CFO, AJ Bergmann, for the forward-looking statements.

Anthony Bergmann
CFO & Corporate Treasurer

Thank you, and good afternoon, everyone.

Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our product candidates, potential regulatory developments involving our product candidates, our future R&D plans, our anticipated conduct and timing of preclinical and clinical studies, enrollment of patients in our clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory inspections, revenue and reimbursement estimates, projected terms of definitive agreements, manufacturing capabilities, our financial position, our possible uses of existing cash and investment resources and statements regarding our litigation with Nippon Shinyaku and NS Pharma Inc., including the nature of the dispute, our expectations regarding any legal proceedings and our ability to commercialize deramiocel independent of our existing distribution agreement.